6533b7dbfe1ef96bd126ff62
RESEARCH PRODUCT
Perception of improved state of health and subjective quality of life in Crohn's disease patients treated with Infliximab.
Ingrid BanovicDaniel GilibertJacques Cosnessubject
medicine.medical_specialtySF-36State of health[SHS.PSY]Humanities and Social Sciences/PsychologyDisease03 medical and health sciences[ SHS.PSY ] Humanities and Social Sciences/Psychology0302 clinical medicineQuality of lifeRefractoryInternal medicinemedicine030212 general & internal medicineDepression (differential diagnoses)ComputingMilieux_MISCELLANEOUSCrohn's diseasebusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryGastroenterologyGeneral Medicinemedicine.diseaseInfliximab3. Good healthPhysical therapy030211 gastroenterology & hepatologybusinessmedicine.drugdescription
International audience; UNLABELLED: BACKGROUND AND AIMS AND METHOD: Although Infliximab is a very potent therapy of refractory Crohn's disease, its administration requires iterative infusions in hospital and there are concerns regarding its long-term safety. The aim of this study was to assess in a sample of 51 patients suffering from CD the impact of type of treatment (intravenous Infliximab versus conventional therapy without Infliximab) on the evaluation of the state of health (CGI) and the quality of life (MOS-SF36). Secondary variables were also assessed: the impact of depression (MADRS), the impact of activity of the disease (Harvey-Bradshaw Index). RESULTS: Overall, the assessments made using the CGI and the SF-36 revealed that the two types of treatment did not differ on the assessment of state of health and quality of life. A downward influence of depression and activity of the disease was observed. CONCLUSION: Patients considered more efficacy of Infliximab than its potential side effects. It seems important to assess and to consider depression in order to improve medical care setting of Crohn's disease.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-02-01 |